FEBRUARY 2018
H
business elite canada 13
as well as other innovative companies will
also further promote collaboration, which
is a key element in fostering and maintain-
ing an innovative environment”, he added
In 2015, Technoparc Montréal got interna-
tional recognition with the establishment
of Green Cross Biotherapeutics’ North
American headquarters. Green Cross Cor-
poration, the parent company in South
Korea, is a multinational enterprise spe-
cialized in pharmaceutical and biotech-
nologies. Considered to be the largest in-
vestment in Canadian Biopharma in over a
decade, this $400-million investment will
introduce Canada’s only manufacturing fa-
cility of plasma-derived protein products,
Intravenous Immunoglobulin and Albumin.
The arrival of Green Cross Biotherapeutics
further reinforces Technoparc Montréal’s
ability to attract international companies.
